Khalili Nahid, Rostami Zohreh, Kalantar Ebrahim, Einollahi Behzad
Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran.
Nephrourol Mon. 2013 Spring;5(2):753-7. doi: 10.5812/numonthly.10773. Epub 2013 Mar 30.
Chronic renal failure is an important and common complication of diabetes mellitus; hence, renal transplantation is a frequent and the acceptable treatment in patients with diabetic nephropathy requiring renal replacement therapy. On the other hand, renal transplantation and its conventional treatment can lead to increased diabetes outbreak in normoglycemic recipients. Also, uncontrolled hyperglycemia may be increased and allograft lost thus decreasing patient survival.
We aimed to assess the frequency of hyperglycemia in transplant patients and its risk factors.
A large retrospective study was performed on 3342 adult kidney transplant recipients between 2008 and 2010. Demographic and laboratory data were gathered for each patient. All tests were done in a single laboratory and hyperglycemia was defined as a fasting plasma glucose of > 125 mg/dL. Univariate and multivariate logistic regression analyses were used to determine the risk factors of hyperglycemia following kidney transplantation.
There were 2120 (63.4%) males and 1212 (36.3%) females. Prevalence of hyperglycemia was 22.5%. By univariate linear regression, hyperglycemia was significantly higher in patients with CMV infection (P = 0.001), elevated serum creatinine (P = 0.000), low HDL (P = 0.01), and increased blood levels of cyclosporine (P = 0.000). After adjusting for covariates by multivariate logistic regression, the hyperglycemia rate was significantly higher for patients with Cyclosporine trough level > 250 (P = 0.000), serum creatinine > 1.5 (P = 0.000) and HDL < 45 (P = 0.03).
This study indicated that hyperglycemia is a common metabolic disorder in Iranian kidney transplant patients. Risk factors for hyperglycemia were higher Cyclosporine level, impaired renal function, and reduced HDL value.
慢性肾衰竭是糖尿病的一种重要且常见的并发症;因此,肾移植是需要肾脏替代治疗的糖尿病肾病患者常用且可接受的治疗方法。另一方面,肾移植及其传统治疗可能导致血糖正常的受者糖尿病发病率增加。此外,血糖控制不佳可能会加重,导致移植肾丧失,从而降低患者生存率。
我们旨在评估移植患者高血糖的发生率及其危险因素。
对2008年至2010年间的3342例成年肾移植受者进行了一项大型回顾性研究。收集了每位患者的人口统计学和实验室数据。所有检测均在单一实验室进行,高血糖定义为空腹血糖>125mg/dL。采用单因素和多因素逻辑回归分析确定肾移植后高血糖的危险因素。
男性2120例(63.4%),女性1212例(36.3%)。高血糖患病率为22.5%。单因素线性回归分析显示,巨细胞病毒感染患者(P = 0.001)、血清肌酐升高(P = 0.000)、高密度脂蛋白降低(P = 0.01)以及环孢素血药浓度升高(P = 0.000)的患者高血糖发生率显著更高。多因素逻辑回归分析校正协变量后,环孢素谷浓度>250(P = 0.000)、血清肌酐>1.5(P = 0.000)和高密度脂蛋白<45(P = 0.03)的患者高血糖发生率显著更高。
本研究表明,高血糖是伊朗肾移植患者常见的代谢紊乱。高血糖的危险因素包括环孢素水平升高、肾功能受损和高密度脂蛋白值降低。